Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-<i>N</i>-(2-aryl-1<i>H</i>-benzo[d]imidazo-5-yl)isoxazole-4-carboxamide analogues as selective FLT3 inhibitors
Journal of enzyme inhibition and medicinal chemistry